Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.9% Following Insider Selling

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 4.9% during mid-day trading on Friday following insider selling activity. The stock traded as low as $6.52 and last traded at $6.57. 1,149,152 shares changed hands during trading, a decline of 80% from the average session volume of 5,710,360 shares. The stock had previously closed at $6.91.

Specifically, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several research firms recently weighed in on RXRX. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Trading Down 4.9 %

The firm has a 50 day moving average price of $6.65 and a two-hundred day moving average price of $7.61. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -4.52 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.43) EPS. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in RXRX. Benjamin Edwards Inc. increased its stake in Recursion Pharmaceuticals by 13,196.3% in the third quarter. Benjamin Edwards Inc. now owns 162,481 shares of the company’s stock valued at $1,071,000 after purchasing an additional 161,259 shares in the last quarter. Erste Asset Management GmbH bought a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $234,000. Arete Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $77,000. Rockefeller Capital Management L.P. bought a new position in Recursion Pharmaceuticals in the third quarter worth approximately $439,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Recursion Pharmaceuticals by 2.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock valued at $14,108,000 after acquiring an additional 43,078 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.